Liposomes with high encapsulation capacity for paclitaxel: Preparation, characterisation and in vivo anticancer effect

Abstract

Paclitaxel (PTX) is approved for the treatment of ovarian and breast cancer. The commercially available preparation of PTX, Cremophor EL® is associated with hypersensitivity reactions in spite of a suitable premedication. In general, the developed liposomal PTX formulations are troubled with low PTX encapsulation capacity (maximal content, 3 mol%) and accompanied by PTX crystallisation. The application of “pocket-forming” lipids significantly increased the encapsulation capacity of PTX in the liposomes up to 10 mol%. Stable lyophilised preparation of PTX (7 mol%) encapsulated in the liposomes composed of SOPC/POPG/MOPC (molar ratio, 60:20:20) doped with 5 mol% vitamin E had the size distribution of 180–190 nm (PDI, 0.1) with ζ-potential of −31 mV. Sucrose was found to be a suitable cryoprotectant at the lipid:sugar molar ratios of 1:5–1:10. This liposomal formulation did not show any evidence of toxicity in C57BL/6 mice treated with the highest doses of PTX (100 mg/kg administered as a single dose and 150 mg/kg as a cumulative dose applied in three equivalent doses in 48-h intervals). A dose-dependent anticancer effect was found in both hollow fibre implants and syngenic B16F10 melanoma mouse tumour models. © 2009 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 99: 2309–2319, 2010